Patents by Inventor Martin A. Billeter
Martin A. Billeter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9623098Abstract: The present invention relates to combined vaccines against measles and human papilloma virus (HPV). In particular, the invention relates to recombinant measles virus vectors containing heterologous nucleic acid encoding single or several antigens derived from HPV, preferably, the major capside antigen L1, the minor capside antigen L2, the early gene E6 and the early gene E7 oncoproteins of HPV type 16, and optionally of types 18, 6 and 11. In a first embodiment, prophylactic vaccines are generated expressing HPV antigens, preferably L1 and/or L2 such that they induce a potent long-lasting immune response in mammals, preferably humans, to protect against HPV and MV infection. In another embodiment, therapeutic vaccines are generated expressing E6 and E7 proteins, and optionally L1 and L2, such that they induced strong immune responses will resolve persistent HPV infections at early or late stages, including HPV-induced cervical carcinoma.Type: GrantFiled: May 26, 2009Date of Patent: April 18, 2017Assignee: Cadila Healthcare LimitedInventors: Sanjeev K. Mendiretta, Reinhard Glueck, Viviana Giannino, Giuseppina Cantarella, Francesca Scuderi, Martin Billeter, Agata Fazzio
-
Patent number: 9308250Abstract: A combined measles-malaria vaccine containing different attenuated recombinant measles-malaria vectors comprising a heterologous nucleic acid encoding several Plasmodium falciparum antigens is described. Preferably, it relates to viral vectors that comprise nucleic acids encoding the circumsporozoite (CS) protein of P. falciparum, the merozoite surface protein 1 (MSP-1) of P. falciparum, and its derivatives (p-42; p-83-30-38) in its glycosylated and secreted forms, and apical membrane antigen1 (AMA1) of P. falciparum, in its anchored or secreted form. The viral vector stems from an attenuated measles virus, based on a strain that is used as a vaccine and is efficient in delivering the gene of interest and that binds to and infects the relevant immune cells efficiently.Type: GrantFiled: September 15, 2014Date of Patent: April 12, 2016Assignee: Cadila Healthcare LimitedInventors: Reinhard Glueck, Agata Fazio, Viviana Gianino, Martin A. Billeter
-
Patent number: 9119815Abstract: A combined measles-malaria vaccine containing different attenuated recombinant measles-malaria vectors comprising a heterologous nucleic acid encoding several Plasmodium falciparum antigens is described. Preferably, it relates to viral vectors that comprise nucleic acids encoding the circumsporozoite (CS) protein of P. falciparum, the merozoite surface protein 1 (MSP-1) of P. falciparum, and its derivatives (p-42; p-83-30-38) in its glycosylated and secreted forms, and apical membrane antigen1 (AMA1) of P. falciparum, in its anchored or secreted form. The viral vector stems from an attenuated measles virus, based on a strain that is used as a vaccine and is efficient in delivering the gene of interest and that binds to and infects the relevant immune cells efficiently.Type: GrantFiled: May 3, 2010Date of Patent: September 1, 2015Assignee: CADILA HEALTHCARE LIMITEDInventors: Reinhard Glueck, Agata Fazio, Viviana Giannino, Martin A Billeter
-
Publication number: 20150071876Abstract: A combined measles-malaria vaccine containing different attenuated recombinant measles-malaria vectors comprising a heterologous nucleic acid encoding several Plasmodium falciparum antigens is described. Preferably, it relates to viral vectors that comprise nucleic acids encoding the circumsporozoite (CS) protein of P. falciparum, the merozoite surface protein 1 (MSP-1) of P. falciparum, and its derivatives (p-42; p-83-30-38) in its glycosylated and secreted forms, and apical membrane antigen1 (AMA1) of P. falciparum, in its anchored or secreted form. The viral vector stems from an attenuated measles virus, based on a strain that is used as a vaccine and is efficient in delivering the gene of interest and that binds to and infects the relevant immune cells efficiently.Type: ApplicationFiled: September 15, 2014Publication date: March 12, 2015Applicant: CADILA HEALTHCARE LIMITEDInventors: Reinhard GLUECK, Agata FAZIO, Viviana GIANINO, Martin A. BILLETER
-
Publication number: 20120121538Abstract: A combined measles-malaria vaccine containing different attenuated recombinant measles-malaria vectors comprising a heterologous nucleic acid encoding several Plasmodium falciparum antigens is described. Preferably, it relates to viral vectors that comprise nucleic acids encoding the circumsporozoite (CS) protein of P. falciparum, the merozoite surface protein 1 (MSP-1) of P. falciparum, and its derivatives (p-42; p-83-30-38) in its glycosylated and secreted forms, and apical membrane antigen1 (AMA1) of P. falciparum, in its anchored or secreted form. The viral vector stems from an attenuated measles virus, based on a strain that is used as a vaccine and is efficient in delivering the gene of interest and that binds to and infects the relevant immune cells efficiently.Type: ApplicationFiled: May 3, 2010Publication date: May 17, 2012Applicant: CADILA HEALTHCARE LIMITEDInventors: Reinhard Glueck, Agata Fazzio, Viviana Gianino, Martin A. Billeter
-
Patent number: 8158416Abstract: The present invention relates, in general, to a methodology for the generation of nonsegmented negative-strand RNA viruses (Pringle, 1991) from cloned deoxyribonucleic acid (cDNA). Such rescued viruses are suitable for use as vaccines, or alternatively, as plasmids in somatic gene therapy applications. The invention also relates to cDNA molecules suitable as tools in this methodology and to helper cell lines allowing the direct rescue of such viruses. Measles virus (MV) is used as a mode for other representatives of the Mononegavirales, in particular the family Paramyxoviridae.Type: GrantFiled: July 1, 2011Date of Patent: April 17, 2012Assignee: Crucell Switzerland AGInventors: Martin A. Billeter, Pius Spielhofer, Karin Kalin, Frank Radecke, Henriette Schneider
-
Publication number: 20120003264Abstract: The present invention relates, in general, to a methodology for the generation of nonsegmented negative-strand RNA viruses (Pringle, 1991) from cloned deoxyribonucleic acid (cDNA). Such rescued viruses are suitable for use as vaccines, or alternatively, as plasmids in somatic gene therapy applications. The invention also relates to cDNA molecules suitable as tools in this methodology and to helper cell lines allowing the direct rescue of such viruses. Measles virus (MV) is used as a mode for other representatives of the Mononegavirales, in particular the family Paramyxoviridae.Type: ApplicationFiled: July 1, 2011Publication date: January 5, 2012Applicant: CRUCELL SWITZERLAND AGInventors: Martin A. Billeter, Pius Spielhofer, Karin Kälin, Frank Radecke, Henriette Schneider
-
Patent number: 7993924Abstract: The present invention relates, in general, to a methodology for the generation of nonsegmented negative-strand RNA viruses (Pringle, 1991) from cloned deoxyribonucleic acid (cDNA). Such rescued viruses are suitable for use as vaccines, or alternatively, as plasmids in somatic gene therapy applications. The invention also relates to cDNA molecules suitable as tools in this methodology and to helper cell lines allowing the direct rescue of such viruses. Measles virus (MV) is used as a mode for other representatives of the Mononegavirales, in particular the family Paramyxoviridae.Type: GrantFiled: September 6, 2007Date of Patent: August 9, 2011Assignee: Crucell Switzerland AGInventors: Martin A. Billeter, Pius Spielhofer, Karin Kälin, Frank Radecke, Henriette Schneider
-
Publication number: 20110129493Abstract: The present invention relates to combined vaccines against measles and human papilloma virus (HPV). In particular, the invention relates to recombinant measles virus vectors containing heterologous nucleic acid encoding single or several antigens derived from HPV, preferably, the major capside antigen L1, the minor capside antigen L2, the early gene E6 and the early gene E7 oncoproteins of HPV type 16, and optionally of types 18, 6 and 11. In a first embodiment, prophylactic vaccines are generated expressing HPV antigens, preferably L1 and/or L2 such that they induce a potent long-lasting immune response in mammals, preferably humans, to protect against HPV and MV infection. In another embodiment, therapeutic vaccines are generated expressing E6 and E7 proteins, and optionally L1 and L2, such that they induced strong immune responses will resolve persistent HPV infections at early or late stages, including HPV-induced cervical carcinoma.Type: ApplicationFiled: May 26, 2009Publication date: June 2, 2011Inventors: Sanjeev K. Mendiretta, Reinhard Glueck, Viviana Giannino, Giuseppina Cantarella, Francesca Scuderi, Martin Billeter, Agata Fazzio
-
Patent number: 7851214Abstract: The present invention relates, in general, to a methodology or the generation of nonsegmented negative-strand RNA viruses (Pringle, 1991) from cloned deoxyribonucleic acid (cDNA). Such rescued viruses are suitable for use as vaccines, or alternatively, as plasmids in somatic gene therapy applications. The invention also relates to cDNA molecules suitable as tools in this methodology and to helper cell lines allowing the direct rescue of such viruses. Measles virus (MV) is used as a model for other representatives of the Mononegavirales, in particular the family Paramyxoviridae.Type: GrantFiled: December 27, 2005Date of Patent: December 14, 2010Assignee: Crucell Switzerland AGInventors: Martin A. Billeter, Pius Spielhofer, Karin Kälin, Frank Radecke, Henriette Schneider
-
Patent number: 7402429Abstract: The present invention relates, in general, to a methodology for the generation or nonsegmented negative-strand RNA viruses (Pringle, 1991) from cloned deoxyribonucleic acid (cDNA). Such rescued viruses are suitable for use as vaccines, or alternatively, as plasmids in somatic gene therapy applications. The invention also relates to cDNA molecules suitable as tools in this methodology and to helper cell lines allowing the direct rescue of such viruses. Measles virus (MV) is used as a model for other representatives of the Mononegavirales, in particular the family Paramyxoviridae.Type: GrantFiled: August 9, 1996Date of Patent: July 22, 2008Assignee: Schweiz Serum & Impfinstitut BernInventors: Martin A. Billeter, Pius Spielhofer, Karin Kälin, Frank Radecke, Henriette Schneider
-
Publication number: 20080124803Abstract: The present invention relates, in general, to a methodology for the generation of nonsegmented negative-strand RNA viruses (Pringle, 1991) from cloned deoxyribonucleic acid (cDNA). Such rescued viruses are suitable for use as vaccines, or alternatively, as plasmids in somatic gene therapy applications. The invention also relates to cDNA molecules suitable as tools in this methodology and to helper cell lines allowing the direct rescue of such viruses. Measles virus (MV) is used as a mode for other representatives of the Mononegavirales, in particular the family Paramyxoviridae.Type: ApplicationFiled: September 6, 2007Publication date: May 29, 2008Applicant: Crucell Holland B.V.Inventors: Martin A. Billeter, Pius Spielhofer, Karin Kalin, Frank Radecke, Henriette Schneider
-
Publication number: 20070280961Abstract: The present invention relates, in general, to a methodology or the generation of nonsegmented negative-strand RNA viruses (Pringle, 1991) from cloned deoxyribonucleic acid (cDNA). Such rescued viruses are suitable for use as vaccines, or alternatively, as plasmids in somatic gene therapy applications. The invention also relates to cDNA molecules suitable as tools in this methodology and to helper cell lines allowing the direct rescue of such viruses. Measles virus (MV) is used as a model for other representatives of the Mononegavirales, in particular the family Paramyxoviridae.Type: ApplicationFiled: December 27, 2005Publication date: December 6, 2007Applicant: Schweiz. Serum & Impfinstitut BernInventors: Martin Billeter, Pius Spielhofer, Karin Kalin, Frank Radecke, Henriette Schneider